RSK Potentially Possesses a Safer Toxicity Profile Than the Competition - A Patent Review

July 13, 2016 - Expert key opinion leader Dr. Deborah A. Lannigan from Vanderbilt University recently published "that targeting the downstream effectors of MEK1/2, like RSK, are an untapped source of drug targets and that they will generate less side effects than MEK1/2 inhibitors because they regulated fewer effectors". She went on to mention that "based on overwhelming evidence that RSK is involved in a number of diseases that have high moralities it seems surprising that there are no RSK modulators that have pharmacokinetic properties suitable for in vivo use". Read the abstract here